Evidence map›Paper›PMID 41852005›Full record

ReviewArchives of Iranian medicine2025

Medical Treatment of Hyperthyroidism; Efficacy and Safety Considerations.

Fereidoun Azizi, Hengameh Abdi, Seyed Alireza Ebadi, Ladan Mehran, Atieh Amouzegar

Abstract readReview
In one paragraph

Review in Archives of Iranian medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fereidoun AziziEndocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-6470-2517
Hengameh AbdiEndocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-6850-0090
Seyed Alireza EbadiDepartment of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ladan MehranEndocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Atieh AmouzegarEndocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-9433-9408

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antithyroid drugs (ATDs) are often the first treatment option for hyperthyroidism due to their efficacy and safety profile. Long-term ATD treatment can effectively control hyperthyroidism and prevent relapse. In this review, we summarize the findings of clinical trials and clinical experiences on the use of ATD treatment for hyperthyroidism. We discuss the efficacy and safety of ATD treatment, as well as the optimal duration of treatment. The evidence suggests that ATD therapy is selected as initial therapy, treatment of relapse of hyperthyroidism and in patients with persistent elevation of TSH receptor antibodies after 18 months of ATD therapy. Long-term ATD treatment can be an effective and safe option for management of many patients with hyperthyroidism. However, additional studies are needed to establish the most efficacious treatment duration and to identify patients who are most likely to benefit from long-term ATD treatment.

Indexed as

Antithyroid AgentsHyperthyroidismHumansTreatment OutcomeAntithyroid AgentsAntithyroid drugEfficacyHyperthyroidismSafety

Identifiers

PMID41852005
PMCPMC13000336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.